,Article,Date,Symbol,Time,Title,Url
0,"   By Deena Beasley  Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.The study found that treatment with Kalydeco and the experimental drug VX-661 for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations.VX-661 would be the second drug from Vertex that works by treating the underlying cause of cystic fibrosis, a rare genetic disease that impairs the lungs and digestive system.The disease is caused by defective or missing CF transmembrane conductane regulator (CFTR) proteins. Kalydeco is designed for patients with the most common CFTR mutation, while VX-661 aims to treat patients with a different mutation that affects protein function.The Phase 2 trial involved patients with both mutations who were already taking Kalydeco. ""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee.That trial will answer the question of whether a combination of Vertex drugs is effective in patients with two copies of the gene mutation not currently addressed by Kalydeco - a market representing about half of the 30,000 cystic fibrosis patients in the United States.A positive result ""would be transformative to the cystic fibrosis community,"" Yee said. The most common side effects seen during the Phase 2 trial included cough, headache and upper respiratory tract infection.But ISI Group analyst Mark Schoenebaum cautioned that Vertex has not disclosed results from the mid-stage trial for patients treated with a placebo.Vertex also announced that first quarter sales of Kalydeco totaled $100 million, which fell short of the average analyst estimate of $107 million, according to Wells Fargo Securities. Separately, The company reported an adjusted first quarter loss of $1.00 per share, also below the average analyst per-share loss estimate of 67 cents, according to Thomson Reuters I/B/E/S.Vertex said it would discontinue research into treatments for hepatitis C, a market now dominated by sales of Gilead Sciences Inc's Sovaldi. Vertex late last year sold off its non-North America royalty rights to hepatitis C drug Incivek.Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $5.30 at $74.25 after hours. (Reporting By Deena Beasley; Editing by David Gregorio and Alden Bentley)",2014-05-01,VRTX,"Thu May 1, 2014 | 7:15pm EDT",Vertex says cystic fibrosis drugs shown to boost lung function,http://www.reuters.com//article/us-vertex-idUSKBN0DH3DM20140501?type=companyNews
1,"  (Adds analyst comment, details, background, byline, updates share price)By Deena BeasleyMay 1 Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.The study found that treatment with Kalydeco and the experimental drug VX-661 for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations.VX-661 would be the second drug from Vertex that works by treating the underlying cause of cystic fibrosis, a rare genetic disease that impairs the lungs and digestive system.The disease is caused by defective or missing CF transmembrane conductane regulator (CFTR) proteins. Kalydeco is designed for patients with the most common CFTR mutation, while VX-661 aims to treat patients with a different mutation that affects protein function. The Phase 2 trial involved patients with both mutations who were already taking Kalydeco.""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee.That trial will answer the question of whether a combination of Vertex drugs is effective in patients with two copies of the gene mutation not currently addressed by Kalydeco - a market representing about half of the 30,000 cystic fibrosis patients in the United States. A positive result ""would be transformative to the cystic fibrosis community,"" Yee said.The most common side effects seen during the Phase 2 trial included cough, headache and upper respiratory tract infection. But ISI Group analyst Mark Schoenebaum cautioned that Vertex has not disclosed results from the mid-stage trial for patients treated with a placebo.Vertex also announced that first quarter sales of Kalydeco totaled $100 million, which fell short of the average analyst estimate of $107 million, according to Wells Fargo Securities.Separately, The company reported an adjusted first quarter loss of $1.00 per share, also below the average analyst per-share loss estimate of 67 cents, according to Thomson Reuters I/B/E/S.Vertex said it would discontinue research into treatments for hepatitis C, a market now dominated by sales of Gilead Sciences Inc's Sovaldi. Vertex late last year sold off its non-North America royalty rights to hepatitis C drug Incivek.Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $5.30 at $74.25 after hours.   (Reporting By Deena Beasley; Editing by David Gregorio and Alden Bentley)",2014-05-01,VRTX,"Thu May 1, 2014 | 6:05pm EDT",UPDATE 1-Vertex says cystic fibrosis drugs shown to boost lung function,http://www.reuters.com//article/vertex-idUSL2N0NN1TX20140501?type=companyNews
2,"  May 1 Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco with an experimental compound was shown to improve lung function in a mid-stage trial, and its shares rose 10 percent after the news.The study found that treatment with both drugs for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations. ""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee. The most common side effects seen during the trial included cough, headache and upper respiratory tract infection. Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $7.04 at $75.99 after hours.   (Reporting By Deena Beasley; Editing by David Gregorio)",2014-05-01,VRTX,"Thu May 1, 2014 | 4:56pm EDT","Vertex cystic fibrosis drugs shown to boost lung function, shrs rise",http://www.reuters.com//article/vertex-idUSL2N0NN1S020140501?type=companyNews
3,"   By Deena Beasley  Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.The study found that treatment with Kalydeco and the experimental drug VX-661 for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations.If eventually approved by regulators, VX-661 would be the second drug from Vertex that works by treating the underlying cause of cystic fibrosis, a rare genetic disease that impairs the lungs and digestive system.The disease is caused by defective or missing CF transmembrane conductane regulator (CFTR) proteins. Kalydeco is designed for patients with certain CFTR mutation. VX-661 is being tested in combination with Kalydeco, as in this Phase 2 trial, and in patients with different genetic mutations.""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee. That trial will answer the question of whether a combination of Vertex drugs is effective in patients with two copies of the gene mutation not currently addressed by Kalydeco - a market representing about half of the 30,000 cystic fibrosis patients in the United States.A positive result ""would be transformative to the cystic fibrosis community,"" Yee said.The most common side effects seen during the Phase 2 trial included cough, headache and upper respiratory tract infection. But ISI Group analyst Mark Schoenebaum cautioned that Vertex has not disclosed results from the mid-stage trial for patients treated with a placebo.Vertex also announced that first quarter sales of Kalydeco totaled $100 million, which fell short of the average analyst estimate of $107 million, according to Wells Fargo Securities.Separately, The company reported an adjusted first quarter loss of $1.00 per share, also below the average analyst per-share loss estimate of 67 cents, according to Thomson Reuters I/B/E/S. Vertex said it would discontinue research into treatments for hepatitis C, a market now dominated by sales of Gilead Sciences Inc's Sovaldi. Vertex late last year sold off its non-North America royalty rights to hepatitis C drug Incivek.Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $5.30 at $74.25 after hours.(This story clarifies in fourth paragraph that Kalydeco is not used for patients with the most common genetic mutation associated with cystic fibrosis) (Reporting By Deena Beasley; Editing by David Gregorio and Alden Bentley)",2014-05-02,VRTX,"Thu May 1, 2014 | 8:51pm EDT",Vertex says cystic fibrosis drugs shown to boost lung function,http://www.reuters.com//article/us-vertex-idUSKBN0DH3DM20140502?type=companyNews
4,"  (Clarifies in fourth paragraph that Kalydeco is not used for patients with the most common genetic mutation associated with cystic fibrosis)By Deena BeasleyMay 1 Vertex Pharmaceuticals Inc on Thursday said a combination of its cystic fibrosis drug Kalydeco and an experimental compound was shown to improve lung function in a mid-stage trial, sending its shares up nearly 8 percent.The study found that treatment with Kalydeco and the experimental drug VX-661 for 28 days resulted in a 4.6 percentage point improvement in mean lung function for patients with two specific genetic mutations.If eventually approved by regulators, VX-661 would be the second drug from Vertex that works by treating the underlying cause of cystic fibrosis, a rare genetic disease that impairs the lungs and digestive system.The disease is caused by defective or missing CF transmembrane conductane regulator (CFTR) proteins. Kalydeco is designed for patients with certain CFTR mutation. VX-661 is being tested in combination with Kalydeco, as in this Phase 2 trial, and in patients with different genetic mutations. ""It is good data and some believe it does have an incremental positive read-through to the all-important Phase 3 data later this summer,"" said RBC Capital Markets analyst Michael Yee.That trial will answer the question of whether a combination of Vertex drugs is effective in patients with two copies of the gene mutation not currently addressed by Kalydeco - a market representing about half of the 30,000 cystic fibrosis patients in the United States. A positive result ""would be transformative to the cystic fibrosis community,"" Yee said.The most common side effects seen during the Phase 2 trial included cough, headache and upper respiratory tract infection.But ISI Group analyst Mark Schoenebaum cautioned that Vertex has not disclosed results from the mid-stage trial for patients treated with a placebo. Vertex also announced that first quarter sales of Kalydeco totaled $100 million, which fell short of the average analyst estimate of $107 million, according to Wells Fargo Securities.Separately, The company reported an adjusted first quarter loss of $1.00 per share, also below the average analyst per-share loss estimate of 67 cents, according to Thomson Reuters I/B/E/S.Vertex said it would discontinue research into treatments for hepatitis C, a market now dominated by sales of Gilead Sciences Inc's Sovaldi. Vertex late last year sold off its non-North America royalty rights to hepatitis C drug Incivek.Shares of Vertex, which closed at $68.95 in regular Nasdaq trading, were up $5.30 at $74.25 after hours.   (Reporting By Deena Beasley; Editing by David Gregorio and Alden Bentley)",2014-05-02,VRTX,"Thu May 1, 2014 | 8:37pm EDT",CORRECTED-UPDATE 1-Vertex says cystic fibrosis drugs shown to boost lung function,http://www.reuters.com//article/vertex-idUSL2N0NN1TX20140502?type=companyNews
5,"   By Bill Berkrot  A combination of Vertex Pharmaceuticals Inc's VRTX.O cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering a potential new treatment for thousands more patients with the rare lung disease and sending Vertex shares soaring.The data announced by the company on Tuesday are seen as critically important to Vertex, which is virtually assured of a return to profitability following approval of the therapy.""The data are good and will clearly support worldwide regulatory approval for this drug regimen,"" ISI Group analyst Mark Schoenebaum said in a research note. ""Worldwide peak sales could exceed $3 billion.""Vertex shares were up 42.3 percent at $94.80 on Nasdaq after the company reported its CF drug Kalydeco in combination with its experimental lumacaftor achieved the main goals of the studies called Traffic and Transport in patients with the most common genetic mutation associated with the disease.Based on the results, the company said it would file applications for U.S. and European approval for the combination in the fourth quarter.In the two, 24-week studies of patients 12 years and older with two copies of F508del genetic mutation, the combination therapy led to mean absolute improvements in lung function of between 2.6 and 4 percentage points, which was deemed to be statistically significant. ""(The data) opens up 28,000 F508Delta patients, giving Vertex a multi-billion dollar franchise and essentially a monopoly for years,"" Maxim Group analyst Jason Kolbert said.Kalydeco is approved to treat cystic fibrosis (CF) patients with a different genetic mutation that accounts for about 2,000 patients worldwide. It had sales of $371 million in 2013.About 22,000 CF patients aged 12 and over have two copies of the F508del mutation. Once pediatric trials are completed another 6,000 patients under 12 could become eligible for the treatment.Lung function improvement was measured by FEV1, or the amount of air a patient can exhale in one second. The mean relative improvements in lung function seen for patients from baseline measurements was 4.3 percent to 6.7 percent, the company reported.""On average, people with CF who have two copies of the F508del mutation lose nearly two percent of their lung function each year, underscoring the urgent need for new medicines,"" Dr. Bonnie Ramsey, lead investigator of one of the studies, said in a statement.A pooled analysis of data from the two trials also showed significant reductions of between 30 and 39 percent in the rate of pulmonary exacerbations, or acute worsening of symptoms, for those who got the two drugs compared with the placebo groups. The combination also led to small but statistically significant increases in body mass index. That is viewed as a beneficial as CF patients have trouble gaining weight.Kalydeco (ivacaftor) and lumacaftor address the underlying cause of CF rather than just symptoms of the disease, in which a missing or defective protein called CFTR results in poor flow of salt and water into and out of cells in the lungs. That causes a buildup of thick, sticky mucus that can lead to chronic lung infections, progressive lung damage and death at an early age.The two studies involved a total of about 1,100 patients with each trial having two active treatment dosing regimens and a placebo group.Among those who received the combination, 4.2 percent dropped out due to adverse side effects compared with a 1.6 percent dropout rate in the placebo group. The most common adverse side effects were infective pulmonary exacerbation, cough, headache and increased sputum. (Reporting by Bill Berkrot; additional reporting by Esha Dey in Bangalore; Editing by Bernard Orr and Sofina Mirza-Reid)",2014-06-24,VRTX,"Tue Jun 24, 2014 | 12:10pm EDT",Vertex cystic fibrosis combo succeeds in key late-stage trials,http://www.reuters.com//article/us-vertexcysticfibrosis-idUSKBN0EZ1CZ20140624?type=companyNews
6,"  (Adds analyst forecast, comment; updates share price)By Bill BerkrotJune 24 A combination of Vertex Pharmaceuticals Inc's cystic fibrosis drugs succeeded in improving lung function in a pair of closely watched late-stage trials, likely offering a potential new treatment for thousands more patients with the rare lung disease and sending Vertex shares soaring.The data announced by the company on Tuesday are seen as critically important to Vertex, which is virtually assured of a  return to profitability following approval of the therapy.""The data are good and will clearly support worldwide regulatory approval for this drug regimen,"" ISI Group analyst Mark Schoenebaum said in a research note. ""Worldwide peak sales could exceed $3 billion.""Vertex shares were up 42.3 percent at $94.80 on Nasdaq after the company reported its CF drug Kalydeco in combination with its experimental lumacaftor achieved the main goals of the studies called Traffic and Transport in patients with the most common genetic mutation associated with the disease.Based on the results, the company said it would file applications for U.S. and European approval for the combination in the fourth quarter. In the two, 24-week studies of patients 12 years and older with two copies of F508del genetic mutation, the combination therapy led to mean absolute improvements in lung function of between 2.6 and 4 percentage points, which was deemed to be statistically significant.""(The data) opens up 28,000 F508Delta patients, giving Vertex a multi-billion dollar franchise and essentially a monopoly for years,"" Maxim Group analyst Jason Kolbert said.Kalydeco is approved to treat cystic fibrosis (CF) patients with a different genetic mutation that accounts for about 2,000 patients worldwide. It had sales of $371 million in 2013. About 22,000 CF patients aged 12 and over have two copies of the F508del mutation. Once pediatric trials are completed another 6,000 patients under 12 could become eligible for the treatment.Lung function improvement was measured by FEV1, or the amount of air a patient can exhale in one second.The mean relative improvements in lung function seen for patients from baseline measurements was 4.3 percent to 6.7 percent, the company reported. ""On average, people with CF who have two copies of the F508del mutation lose nearly two percent of their lung function each year, underscoring the urgent need for new medicines,"" Dr. Bonnie Ramsey, lead investigator of one of the studies, said in a statement.A pooled analysis of data from the two trials also showed significant reductions of between 30 and 39 percent in the rate of pulmonary exacerbations, or acute worsening of symptoms, for those who got the two drugs compared with the placebo groups.The combination also led to small but statistically significant increases in body mass index. That is viewed as a beneficial as CF patients have trouble gaining weight.Kalydeco (ivacaftor) and lumacaftor address the underlying cause of CF rather than just symptoms of the disease, in which a missing or defective protein called CFTR results in poor flow of salt and water into and out of cells in the lungs. That causes a buildup of thick, sticky mucus that can lead to chronic lung infections, progressive lung damage and death at an early age.The two studies involved a total of about 1,100 patients with each trial having two active treatment dosing regimens and a placebo group.Among those who received the combination, 4.2 percent dropped out due to adverse side effects compared with a 1.6 percent dropout rate in the placebo group. The most common adverse side effects were infective pulmonary exacerbation, cough, headache and increased sputum.   (Reporting by Bill Berkrot; additional reporting by Esha Dey in Bangalore; Editing by Bernard Orr and Sofina Mirza-Reid)",2014-06-24,VRTX,"Tue Jun 24, 2014 | 11:45am EDT",UPDATE 2-Vertex cystic fibrosis combo succeeds in key late-stage trials,http://www.reuters.com//article/vertexcysticfibrosis-idUSL4N0P52ZU20140624?type=companyNews
7,     ,2014-06-24,VRTX,"Tue Jun 24, 2014 | 10:53am EDT",Vertex cystic fibrosis combo succeeds in key late stage trials,http://www.reuters.com//article/vertex-cysticfibrosis-idUSL2N0P41QG20140624?type=companyNews
8,"  Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.On Monday, Vertex sent a letter to doctors who treat patients with liver wasting disease to inform them that it would not be available after Oct. 14, a company spokesman confirmed on Wednesday.Vertex said in May during a conference call with analysts that it would withdraw from the hepatitis C market but had not said when it would stop making the drug. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion. Sales began to decline at the end of 2012 as patients began to wait for promising new drugs from competitors, which hit the market at the end of 2013.  The spokesman said the move was due to dwindling patients for the drug and the new treatments that are available. In the first half of the year, Gilead sold about $6 billion of Sovaldi, which has a high cure rate without the risk of the side effects older treatments carried. Johnson & Johnson markets the Vertex hepatitis C treatment outside of the United States.Vertex shares were up 3.7 percent to $88.58 on Wednesday.  (Reporting by Caroline Humer; Editing by Nick Zieminski)",2014-08-13,VRTX,"Wed Aug 13, 2014 | 2:43pm EDT",Vertex to end sales of hepatitis C drug Incivek,http://www.reuters.com//article/us-vertex-hepatitisc-idUSKBN0GD1S520140813?type=companyNews
9,"  Aug 13 Vertex Pharmaceuticals Inc is stopping U.S. sales and distribution of its Incivek hepatitis C treatment, whose use has been largely supplanted by the new Sovaldi drug from Gilead Sciences Inc.On Monday, Vertex sent a letter to doctors who treat patients with liver wasting disease to inform them that it would not be available after Oct. 14, a company spokesman confirmed on Wednesday.Vertex said in May during a conference call with analysts that it would withdraw from the hepatitis C market but had not said when it would stop making the drug. Incivek was approved in 2011 and quickly rose to annual sales of more than $1 billion. Sales began to decline at the end of 2012 as patients began to wait for promising new drugs from competitors, which hit the market at the end of 2013. The spokesman said the move was due to dwindling patients for the drug and the new treatments that are available. In the first half of the year, Gilead sold about $6 billion of Sovaldi, which has a high cure rate without the risk of the side effects older treatments carried. Johnson & Johnson markets the Vertex hepatitis C treatment outside of the United States.Vertex shares were up 3.7 percent to $88.58 on Wednesday.   (Reporting by Caroline Humer; Editing by Nick Zieminski)",2014-08-13,VRTX,"Wed Aug 13, 2014 | 2:42pm EDT",Vertex to end sales of hepatitis C drug Incivek,http://www.reuters.com//article/vertex-hepatitisc-idUSL2N0QJ1YT20140813?type=companyNews
10,"  (Adds analyst forecast, share move)By Bill BerkrotOct 21 A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.The panel of experts said Kalydeco should be approved for patients ages 6 and older with a specific mutation of the R117H gene, of which there are about 500 people in the United States. The FDA usually follows recommendations of its advisory panels, but is not obligated to do so. The agency is expected to make its decision on the expanded approval by the end of the year, Vertex said.The current approval of Kalydeco, known chemically as ivacaftor, covers about 2,600 people in North America, Europe and Australia with a different gene mutation. Vertex has forecast 2014 Kalydeco sales of $470 million to $500 million. Sanford Bernstein analyst Geoffrey Porges said the expanded approval could add about $160 million to annual Kalydeco sales and 50 cents to 55 cents in earnings per share. Kalydeco was the first drug approved that addresses the underlying cause of cystic fibrosis rather than just the symptoms of the life threatening disease. It helps improve breathing by clearing mucus from the airways.Vertex is testing other drugs in combination with Kalydeco in hopes of being able to treat a larger portion of the CF population, which affects about 75,000 people in North America, Europe and Australia.Vertex shares rose 1.6 percent to $109.95 in extended trading from their Nasdaq close at $108.16.   (Reporting by Bill Berkrot; Editing by Diane Craft)",2014-10-21,VRTX,"Tue Oct 21, 2014 | 6:31pm EDT",UPDATE 1-FDA panel votes to expand use of Vertex cystic fibrosis drug,http://www.reuters.com//article/vertex-cysticfibrosis-fda-idUSL2N0SG35A20141021?type=companyNews
11,"  Oct 21 A U.S. Food and Drug Administration advisory panel on Tuesday voted 13-2 to recommend expanding approval of Vertex Pharmaceuticals Inc's cystic fibrosis drug Kalydeco to include a wider range of patients with the rare lung disease, the company said.The panel of experts said Kalydeco should be approved for patients ages 6 and older with a specific mutation of the R117H gene, of which there are about 500 people in the United States.The FDA usually follows recommendations of its advisory panels, but is not obligated to do so. The agency is expected to make its decision on the expanded approval by the end of the year, Vertex said. The current approval of Kalydeco, known chemically as ivacaftor, covers about 2,600 people in North America, Europe and Australia with a different gene mutation. Vertex has forecast 2014 Kalydeco sales of $470 million to $500 million. Kalydeco was the first drug approved that addresses the underlying cause of cystic fibrosis rather than just the symptoms of the life threatening disease. It helps improve breathing by clearing mucus from the airways. Vertex is testing other drugs in combination with Kalydeco in hopes of being able to treat a larger portion of the CF population, which affects about 75,000 people in North America, Europe and Australia.   (Reporting by Bill Berkrot; Editing by Diane Craft)",2014-10-21,VRTX,"Tue Oct 21, 2014 | 5:41pm EDT",FDA panel votes to expand use of Vertex cystic fibrosis drug,http://www.reuters.com//article/vertex-cysticfibrosis-fda-idUSL2N0SG2XP20141021?type=companyNews
12,"  Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate of the Cystic Fibrosis Foundation.  The foundation plans to use the proceeds of the deal for the development of new therapies for the disease, Royal Pharma said in a statement on Wednesday.Cystic fibrosis is a fatal genetic disease that affects the lungs and digestive system. The disease currently affects about 70,000 children and adults worldwide.   (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)",2014-11-19,VRTX,"Wed Nov 19, 2014 | 5:50pm EST",Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 billion,http://www.reuters.com//article/us-royaltypharma-vertexpharma-deal-idUSKCN0J31C720141119?type=companyNews
13,"  (Adds Breakingviews)Nov 19 Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate of the Cystic Fibrosis Foundation.The foundation plans to use the proceeds of the deal for the development of new therapies for the disease, Royal Pharma said in a statement on Wednesday. Cystic fibrosis is a fatal genetic disease that affects the lungs and digestive system. The disease currently affects about 70,000 children and adults worldwide. (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)",2014-11-19,VRTX,"Wed Nov 19, 2014 | 5:49pm EST",UPDATE 1-Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln,http://www.reuters.com//article/royaltypharma-vertexpharma-deal-idUSL3N0T963R20141119?type=companyNews
14,"  Nov 19 Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.Vertex's cystic fibrosis drug, Kalydeco, was approved by the U.S. Food and Drug Administration in January 2012. Vertex co-developed the drug with an affiliate of the Cystic Fibrosis Foundation. The foundation plans to use the proceeds of the deal for the development of new therapies for the disease, Royal Pharma said in a statement on Wednesday. Cystic fibrosis is a fatal genetic disease that affects the lungs and digestive system. The disease currently affects about 70,000 children and adults worldwide.     (Reporting by Amrutha Penumudi in Bangalore; Editing by Kirti Pandey)",2014-11-19,VRTX,"Wed Nov 19, 2014 | 8:07am EST",Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln,http://www.reuters.com//article/royaltypharma-vertexpharma-deal-idUSL3N0T94BF20141119?type=companyNews
15,"  (The following statement was released by the rating agency) CHICAGO, November 21 (Fitch) Fitch Ratings has affirmed the ratings of RPI  Finance Trust (RPI FT), including the 'BBB-' Issuer Default Rating (IDR),  following the acquisition of royalty-bearing assets linked to Vertex  Pharmaceutical Inc.'s (Vertex) cystic fibrosis treatment Kalydeco. The rating  action applies to approximately $3.3 billion of debt outstanding as of Sept. 30,  2014. The Rating Outlook is Stable.  A full list of rating actions follows at the end of this press release.   KEY RATING DRIVERS -- The acquisition of certain rights to the Kalydeco franchise for $3.3 billion,  while leveraging, is consistent with RPI FT's strategy to invest in long-term  attractive royalty-bearing assets. The purchase mitigates pressure on revenues  as patents lapse for pharmaceuticals that underlie nearly 32% of the company's  royalty stream over the next three years.  -- As a result of the transaction, Fitch expects debt leverage (total debt to  EBITDA) to rise to 4.5x at the end of 2014 from below 2.5x currently. Absent  further-leveraging asset purchases, Fitch sees leverage dropping to below 4x in  2015 and 3x in 2016 driven by a combination of EBITDA growth and rapid debt  reduction facilitated by an excess cash flow recapture provision in the  company's credit facilities.    -- A new investment horizon is approaching and it is expected that by the end of  2015, RPI FT's structure may once again change. It is unknown whether another  division in assets may occur akin to 2011, but initial work toward addressing  the event will likely begin over the near term. RATING SENSITIVITIES An upgrade is unlikely for RPI FT given the company's business strategy is  reliant on active asset purchasing that can stretch leverage to a level no  longer consistent with the current 'BBB-' rating. Uncertainty surrounding the  approaching investment event in 2015 also limits ratings upside.   A downgrade would result from an intention to completely wind down the  royalty-bearing assets, most probable during the investment event, expected to  occur in 2015. A fall in cash flows such that the anticipated total no longer  matches the outstanding debt level would pressure the rating as well. In  addition, downward action would result from an inability or unwillingness to  reduce high debt leverage rapidly following leveraging asset acquisitions. Portfolio life extended by acquisition: Fitch's concern about patent expirations of pharmaceuticals over the next few  years that drive RPI FT's revenues has been addressed by the addition of rights  to the Kalydeco franchise, including developmental projects, as well as  higher-than-expected milestone payments related to sales of Biogen IDEC Inc.'s  multiple sclerosis medicine Tecfidera.  Maturing drugs over the next three years  represented 32% of the company's royalty stream at the end of 2013. Fitch now  sees mid-double-digit revenue and earnings increases over the ratings horizon.  The transaction also increased the average weighted life of the company's  royalty-bearing asset portfolio to around 11 years from eight years.  Leverage temporarily increases: RPI FT's debt leverage will rise to 4.5x at the end of 2014 from approximately  2.3x currently, in conjunction with incremental debt needed to fund the recent  $3.3 billion acquisition. Fitch believes that gross debt leverage will quickly  fall to below 4x in 2015 and below 3x in 2016 driven by debt paydown required by  excess free cash flow recapture in the company's secured term loan B facilities.  The provision calls for 50% or 25% of excess cash flow to be applied to debt  reduction if gross leverage is above or below 3.5x, respectively.  Investment event nearing: An investment event dictated by RPI FT's guidelines must take place in 2015 or  all investment activity will cease. The strategy for the prior event in 2011  resulted in a split (a highly lengthy process) of Royalty Pharma into two new  finance subsidiaries: Royalty Pharma Investments (RPI) and Royalty Pharma Select  (RP Select). It is unknown whether another division in assets may occur, but  initial work toward addressing the event will begin in the near term. Fitch has affirmed the following ratings of RPI FT: --IDR at 'BBB-'; --Senior secured bank loan rating at 'BBB-'. Contact: Primary Analyst Michael Zbinovec Senior Director +1-312-368-3164,  Fitch Ratings, Inc. 70 West Madison Street Chicago, IL 60602 Secondary Analyst Megan Neuburger Senior Director +1-212-908-0501 Chairperson Mike Weaver Managing Director +1-312-368-3156 Media Relations: Brian Bertsch, New York, Tel: +1 212-908-0549, Email:  brian.bertsch@fitchratings.com. Additional information is available at 'www.fitchratings.com'.   Applicable Criteria and Related Research: 'Corporate Rating Methodology' May 28, 2014 Applicable Criteria and Related Research:  Corporate Rating Methodology - Including Short-Term Ratings and Parent and  Subsidiary Linkage here Additional Disclosure  Solicitation Status  here ALL FITCH CREDIT RATINGS ARE SUBJECT TO CERTAIN LIMITATIONS AND DISCLAIMERS.  PLEASE READ THESE LIMITATIONS AND DISCLAIMERS BY FOLLOWING THIS LINK:  here. IN ADDITION, RATING  DEFINITIONS AND THE TERMS OF USE OF SUCH RATINGS ARE AVAILABLE ON THE AGENCY'S  PUBLIC WEBSITE 'WWW.FITCHRATINGS.COM'. PUBLISHED RATINGS, CRITERIA AND  METHODOLOGIES ARE AVAILABLE FROM THIS SITE AT ALL TIMES. FITCH'S CODE OF  CONDUCT, CONFIDENTIALITY, CONFLICTS OF INTEREST, AFFILIATE FIREWALL, COMPLIANCE  AND OTHER RELEVANT POLICIES AND PROCEDURES ARE ALSO AVAILABLE FROM THE 'CODE OF  CONDUCT' SECTION OF THIS SITE. FITCH MAY HAVE PROVIDED ANOTHER PERMISSIBLE  SERVICE TO THE RATED ENTITY OR ITS RELATED THIRD PARTIES. DETAILS OF THIS  SERVICE FOR RATINGS FOR WHICH THE LEAD ANALYST IS BASED IN AN EU-REGISTERED  ENTITY CAN BE FOUND ON THE ENTITY SUMMARY PAGE FOR THIS ISSUER ON THE FITCH  WEBSITE.   ",2014-11-21,VRTX,"Fri Nov 21, 2014 | 1:40pm EST",Fitch Affirms RPI Finance Trust's IDR at 'BBB-'; Outlook Stable,http://www.reuters.com//article/fitch-affirms-rpi-finance-trusts-idr-at-idUSFit84004020141121?type=companyNews
16,"   By Natalie Grover  Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco.Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects to begin a mid-stage study this quarter.The company hopes Resunab will treat every patient suffering from the disease, compared with Kalydeco, which has approval to treat a small section of patients. The disease currently affects 70,000 people worldwide.Kalydeco treats certain underlying genetic mutations behind cystic fibrosis (CF), while Resunab aims to manage the inflammation the disease causes.""We're not focusing on a particular subset of patients, like Vertex's drug,"" Chief Executive Yuval Cohen said.Kalydeco, which was granted fast-track status by the U.S. Food and Drug Administration, received approval in 2012, six years after the company started an early stage trial.Kalydeco, which had sales of about $464 million in 2014, is being tested in combination with other drugs to expand its use. It is expected to generate peak sales of $1.1 billion in 2020, according to Thomson Reuters Cortellis.Resunab could bring in more than $2 billion in U.S. sales treating CF patients, Zacks Investment Research analyst Jason Napodano said.Still, Corbus has a long way to go. ""It's too soon to know how significant Resunab will be ...,"" said a CF Foundation spokeswoman.CF is caused by a missing or defective gene that makes the body produce a thick, sticky mucus resulting in inflammation and bacterial infections. This then causes ""abnormal inflammation,"" which leads to fibrosis, and, eventually, death.""Theoretically, we're targeting all CF patients, because the one thing that all these mutations share is that every single one of them exhibits abnormal inflammation,"" Cohen said. Cohen had helped develop five anti-inflammatory drug candidates as co-founder of Celsus Therapeutics Plc.Since Resunab aims to bring down the abnormal inflammation by mimicking a natural process, Cohen expects it will have a ""good safety profile"". Existing anti-inflammatory drugs are typically associated with serious side-effects and suppress the immune system.Resunab is also being tested to treat scleroderma, an inflammatory skin disorder. A scleroderma approval could add another $2 billion in peak sales, Zacks' Napodano said.Shares of the company, which has a market value of about $80 million, traded over the counter before listing on the Nasdaq in April. (Editing by Sayantani Ghosh and Sriraj Kalluvila)",2015-05-04,VRTX,"Mon May 4, 2015 | 5:45pm EDT",Tiny Corbus looks to take on Vertex with experimental lung drug,http://www.reuters.com//article/us-corbus-cysticfibrosis-idUSKBN0NP21B20150504?type=companyNews
17,"   By Natalie Grover  May 4 Corbus Pharmaceuticals Holdings Inc's  experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's  successful treatment, Kalydeco.Corbus, a tiny biopharmaceutical company, received $5 million from the Cystic Fibrosis Foundation last month to develop the drug, Resunab, and expects to begin a mid-stage study this quarter.The company hopes Resunab will treat every patient suffering from the disease, compared with Kalydeco, which has approval to treat a small section of patients. The disease currently affects 70,000 people worldwide.Kalydeco treats certain underlying genetic mutations behind cystic fibrosis (CF), while Resunab aims to manage the inflammation the disease causes.""We're not focusing on a particular subset of patients, like Vertex's drug,"" Chief Executive Yuval Cohen said.Kalydeco, which was granted fast-track status by the U.S. Food and Drug Administration, received approval in 2012, six years after the company started an early stage trial. Kalydeco, which had sales of about $464 million in 2014, is being tested in combination with other drugs to expand its use.It is expected to generate peak sales of $1.1 billion in 2020, according to Thomson Reuters Cortellis.Resunab could bring in more than $2 billion in U.S. sales treating CF patients, Zacks Investment Research analyst Jason Napodano said. Still, Corbus has a long way to go.""It's too soon to know how significant Resunab will be ...,"" said a CF Foundation spokeswoman.CF is caused by a missing or defective gene that makes the body produce a thick, sticky mucus resulting in inflammation and bacterial infections. This then causes ""abnormal inflammation,"" which leads to fibrosis, and, eventually, death.""Theoretically, we're targeting all CF patients, because the one thing that all these mutations share is that every single one of them exhibits abnormal inflammation,"" Cohen said.Cohen had helped develop five anti-inflammatory drug candidates as co-founder of Celsus Therapeutics Plc.Since Resunab aims to bring down the abnormal inflammation by mimicking a natural process, Cohen expects it will have a ""good safety profile"". Existing anti-inflammatory drugs are typically associated with serious side-effects and suppress the immune system.Resunab is also being tested to treat scleroderma, an inflammatory skin disorder. A scleroderma approval could add another $2 billion in peak sales, Zacks' Napodano said.Shares of the company, which has a market value of about $80 million, traded over the counter before listing on the Nasdaq in April.   (Editing by Sayantani Ghosh and Sriraj Kalluvila)",2015-05-04,VRTX,"Mon May 4, 2015 | 5:40pm EDT",Tiny Corbus looks to take on Vertex with experimental lung drug,http://www.reuters.com//article/corbus-cysticfibrosis-idUSL4N0XS3TH20150504?type=companyNews
18,"  * FDA slated to make decision on treatment on July 5* Analysts say they still expect approval* Vertex's stock up 1.7 pct in afternoon trade   (Recasts, adds details; updates shares)By Natalie Grover and Vidya L NathanMay 8 Staff reviewers from the U.S. FDA questioned whether Vertex Pharmaceuticals Inc's  experimental combination therapy for cystic fibrosis had an added benefit over the company's already approved therapy, Kalydeco, in patients with the most common genetic mutation behind the deadly disease.Vertex's combination of Kalydeco and an experimental compound called lumacaftor was tested against a placebo in patients aged 12 and above with a type of genetic mutation known as F508del, carried by about half of all CF patients. Kalydeco is not currently approved to treat this mutation.If the combination, Orkambi, is approved, Vertex will be eligible to treat about 8,500 patients in the United States, up from the 2,000 Kalydeco currently addresses, said Zachry Barber, the company's senior director of corporate communications.The FDA is slated to make a decision on Orkambi by July 5. U.S. Food and Drug Administration reviewers noted Orkambi's ""relatively small"" treatment effect, but said they were satisfied with its safety profile, in briefing documents released on Friday, (1.usa.gov/1ceMWB6)The combination was tested against a placebo, rather than against its individual components as is typically the case, the reviewers said.This raises the question of whether lumacaftor contributes any added benefit over Kalydeco as a standalone drug, as well as whether Kalydeco by itself has a positive effect on the patient population, they said. Analysts said they still expect the FDA to approve the drug.CF is caused by a missing or defective gene that makes the body produce a thick, sticky mucus resulting in inflammation and recurrent bacterial infections. Most patients die in their mid-twenties.Patients must take a cocktail of vitamins, painkillers and antibiotics to maintain daily functioning. The disease affects about 30,000 people in the United States.A panel of independent advisers to the FDA will make a recommendation on Orkambi on Tuesday. The agency typically follows the panel's recommendations.Vertex's stock was up 1.2 percent in afternoon trading. The shares rose as much as 5 percent to a session high of $131.42 earlier.   (Editing by Joyjeet Das and Simon Jennings)",2015-05-08,VRTX,"Fri May 8, 2015 | 2:13pm EDT",UPDATE 2-FDA staff questions value of Vertex's cystic fibrosis combo,http://www.reuters.com//article/vertex-pharms-fda-idUSL4N0XZ6VB20150508?type=companyNews
19,"  WASHINGTON A divided U.S. Food and Drug Administration advisory committee on Tuesday said research data does not show definitively that Vertex Pharmaceutical Inc's drug lumacaftor has a positive effect on cystic fibrosis patients when used in combination with the company's approved therapy, Kalydeco.The panel reached its decision with only three members voting in favor of efficacy. Four members said data did not show efficacy, while six others said efficacy could not be determined with the data available. The panel is expected to decide within the next hour whether to recommend FDA approval for the combination therapy, which would be sold under the brand name Orkambi.           (Reporting by David Morgan; Editing by Diane Craft)",2015-05-12,VRTX,"Tue May 12, 2015 | 5:57pm EDT",FDA panel fails to find Vertex lumacaftor positive for cystic fibrosis,http://www.reuters.com//article/us-vertex-fda-lumacaftor-idUSKBN0NX2D820150512?type=companyNews
20,"   By David Morgan | WASHINGTON  WASHINGTON A U.S. Food and Drug Administration advisory committee on Tuesday recommended approval of Vertex Pharmaceuticals Inc's combination cystic fibrosis therapy, finding it to be safe and effective for patients ages 12 and up.The recommendation, which came in a 12-1 vote, will now be considered by FDA officials who are expected to decide by July 5 whether to approve the treatment, Orkambi, for sale in the United States. The FDA usually follows the recommendations of its advisory panels but does not have to.""Is the drug going to be approved? Yes,"" said RBC Capital Markets analyst Michael Yee, who forecast annual peak Orkambi sales of up to $5 billion.Yee said the panel vote removed uncertainty that had been  holding back the Vertex share price, and that Orkambi would return the company to profitability.The Vertex stock had been halted during the panel meeting, but when trading resumed shares jumped 7 percent to $132.80. Cystic fibrosis is a life-shortening lung disease that afflicts about 30,000 people in the United States.Orkambi combines the FDA-approved Vertex drug Kalydeco and a new compound called lumacaftor. The treatment targets the most common genetic mutation responsible for cystic fibrosis. Vertex estimates that Orkambi would initially be used to treat about 8,500 patients with the F508del mutation, or 28 percent of U.S. cystic fibrosis sufferers. Kalydeco, the first medicine to address the underlying cause of CF rather than just symptoms, is currently used to treat about 2,000 patients who suffer from a different mutation.  Worldwide, there are an estimated 70,000 CF patients, about half of whom have the F508del mutation Orkambi is designed to treat.    Those patients who were not eligible for Kalydeco are currently treated with a cocktail of vitamins, pain killers and antibiotics to maintain daily functions.Before reaching its final decision, a divided panel was unable to say that lumacaftor had a positive effect when used in  combination with Kalydeco because the data was insufficient to demonstrate the efficacy of Orkambi's separate components.     Agency staff offered a mixed review of the combination last week, raising questions about whether it had an added benefit over Kalydeco alone.The committee also heard compelling and often tearful public testimony from nearly two dozen CF patients, their relatives and advocates, who pleaded that it recommend Orkambi on the hope the treatment could slow or even reverse progression of the disease for some. (Additional reporting by Bill Berkrot in New York; Editing by Diane Craft and Ted Botha)",2015-05-12,VRTX,"Tue May 12, 2015 | 5:57pm EDT",FDA panel recommends Vertex cystic fibrosis treatment,http://www.reuters.com//article/us-vertex-fda-recommendation-idUSKBN0NX2EH20150512?type=companyNews
21,"  (Adds reference to vote on lumacaftor, public witness testimony, analyst comment)By David MorganWASHINGTON May 12 A U.S. Food and Drug Administration advisory committee on Tuesday recommended approval of Vertex Pharmaceuticals Inc's combination cystic fibrosis therapy, finding it to be safe and effective for patients ages 12 and up.The recommendation, which came in a 12-1 vote, will now be considered by FDA officials who are expected to decide by July 5 whether to approve the treatment, Orkambi, for sale in the United States. The FDA usually follows the recommendations of its advisory panels but does not have to.""Is the drug going to be approved? Yes,"" said RBC Capital Markets analyst Michael Yee, who forecast annual peak Orkambi sales of up to $5 billion.Yee said the panel vote removed uncertainty that had been  holding back the Vertex share price, and that Orkambi would return the company to profitability. The Vertex stock had been halted during the panel meeting, but when trading resumed shares jumped 7 percent to $132.80.Cystic fibrosis is a life-shortening lung disease that afflicts about 30,000 people in the United States.Orkambi combines the FDA-approved Vertex drug Kalydeco and a new compound called lumacaftor. The treatment targets the most common genetic mutation responsible for cystic fibrosis. Vertex estimates that Orkambi would initially be used to treat about 8,500 patients with the F508del mutation, or 28 percent of U.S. cystic fibrosis sufferers. Kalydeco, the first medicine to address the underlying cause of CF rather than just symptoms, is currently used to treat about 2,000 patients who suffer from a different mutation.Worldwide, there are an estimated 70,000 CF patients, about half of whom have the F508del mutation Orkambi is designed to treat. Those patients who were not eligible for Kalydeco are currently treated with a cocktail of vitamins, pain killers and antibiotics to maintain daily functions.Before reaching its final decision, a divided panel was unable to say that lumacaftor had a positive effect when used in  combination with Kalydeco because the data was insufficient to demonstrate the efficacy of Orkambi's separate components.Agency staff offered a mixed review of the combination last week, raising questions about whether it had an added benefit over Kalydeco alone.The committee also heard compelling and often tearful public testimony from nearly two dozen CF patients, their relatives and advocates, who pleaded that it recommend Orkambi on the hope the treament could slow or even reverse progression of the disease for some.(Additional reporting by Bill Berkrot in New York; Editing by Diane Craft and Ted Botha)",2015-05-12,VRTX,"Tue May 12, 2015 | 5:01pm EDT",UPDATE 2-US FDA panel recommends Vertex cystic fibrosis treatment,http://www.reuters.com//article/vertex-fda-recommendation-idUSL1N0Y32BY20150512?type=companyNews
22,"  WASHINGTON May 12 A divided U.S. Food and Drug Administration advisory committee on Tuesday said research data does not show definitively that Vertex Pharmaceutical Inc's  drug lumacaftor has a positive effect on cystic fibrosis patients when used in combination with the company's approved therapy, Kalydeco.The panel reached its decision with only three members voting in favor of efficacy. Four members said data did not show efficacy, while six others said efficacy could not be determined with the data available. The panel is expected to decide within the next hour whether to recommend FDA approval for the combination therapy, which would be sold under the brand name Orkambi.   (Reporting by David Morgan; Editing by Diane Craft)",2015-05-12,VRTX,"Tue May 12, 2015 | 3:30pm EDT",FDA panel fails to find Vertex lumacaftor positive for cystic fibrosis,http://www.reuters.com//article/vertex-fda-lumacaftor-idUSL1N0Y31V920150512?type=companyNews
23,"   By Samantha Kareen Nair  Vertex Pharmaceuticals Inc's unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis.Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients aged 12 and above, the U.S. Food and Drug Administration said on Thursday. (1.usa.gov/1KwebV3)Orkambi and Kalydeco aim at fixing the underlying condition caused by the misbehaving gene, unlike current drugs which treat related symptoms.    The combination treats the most common F508del mutation, while Kalydeco alone treats cystic fibrosis patients with a different mutation. Orkambi will carry a wholesale price tag of $259,000 per year in the United States, the company said in a regulatory filing. (1.usa.gov/1HzWyon) Most of the analysts had expected Orkambi to be priced lower than Kalydeco, which costs about $300,000 per year.        Analyst's view on the lower pricing reflects the immediate need for a cure to the larger population at an affordable rate.Cystic fibrosis is caused by a defective gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. Most patients die in their mid-20s. William Blair & Co LLC's Katherine Xu said the ""disease modifying"" Orkambi is expected to generate peak annual sales of about $5.9 billion worldwide.Kalydeco sales rose 25 percent to $463.8 million in 2014. Orkambi is intended to benefit nearly half of the 30,000 Americans affected with cystic fibrosis. Worldwide, about 70,000 people are estimated to have been affected by the disorder.MorningStar Inc's Stefan Quenneville said he expects the drug to win European approval by the end of the year.Vertex Pharma's shares were trading up 2.2 percent at $128.85 on the Nasdaq on Thursday. (Editing by Savio D'Souza and Don Sebastian)",2015-07-02,VRTX,"Thu Jul 2, 2015 | 3:19pm EDT",Vertex Pharma's lung disorder therapy wins FDA nod,http://www.reuters.com//article/us-vertexpharmaceutical-fda-idUSKCN0PC1ZU20150702?type=companyNews
24,"  (Adds pricing)By Samantha Kareen NairJuly 2 Vertex Pharmaceuticals Inc's  unique combination therapy for a rare lung disorder was given the green light by U.S. health regulators, extending the company's reach to the most common form of genetic mutation responsible for cystic fibrosis.Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients aged 12 and above, the U.S. Food and Drug Administration said on Thursday. (1.usa.gov/1KwebV3)Orkambi and Kalydeco aim at fixing the underlying condition caused by the misbehaving gene, unlike current drugs which treat related symptoms.The combination treats the most common F508del mutation, while Kalydeco alone treats cystic fibrosis patients with a different mutation. Orkambi will carry a wholesale price tag of $259,000 per year in the United States, the company said in a regulatory filing. (1.usa.gov/1HzWyon)Most of the analysts had expected Orkambi to be priced lower than Kalydeco, which costs about $300,000 per year. Analyst's view on the lower pricing reflects the immediate need for a cure to the larger population at an affordable rate.Cystic fibrosis is caused by a defective gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. Most patients die in their mid-20s.William Blair & Co LLC's Katherine Xu said the ""disease modifying"" Orkambi is expected to generate peak annual sales of about $5.9 billion worldwide. Kalydeco sales rose 25 percent to $463.8 million in 2014.Orkambi is intended to benefit nearly half of the 30,000 Americans affected with cystic fibrosis. Worldwide, about 70,000 people are estimated to have been affected by the disorder.MorningStar Inc's Stefan Quenneville said he expects the drug to win European approval by the end of the year.Vertex Pharma's shares were trading up 2.2 percent at $128.85 on the Nasdaq on Thursday.   (Editing by Savio D'Souza and Don Sebastian)",2015-07-02,VRTX,"Thu Jul 2, 2015 | 3:19pm EDT",UPDATE 2-Vertex Pharma's lung disorder therapy wins FDA nod,http://www.reuters.com//article/vertexpharmaceutical-fda-idUSL3N0ZI4V420150702?type=companyNews
25,"  July 2 Vertex Pharmaceuticals Inc's  combination therapy for a rare lung disorder was approved by U.S. health regulators,  extending the company's reach to now treat the most common form of genetic mutation responsible for cystic fibrosis.Orkambi, a combination of Vertex's approved drug Kalydeco and a new compound called lumacaftor, is intended for patients aged 12 and above, the U.S. Food and Drug Administration said on Thursday. (1.usa.gov/1KwebV3) With the approval, Orkambi will be available to about 8,500 patients in the United States, more than the 2,000 who take Kalydeco, which targets a different genetic mutation that causes cystic fibrosis.  Cystic fibrosis is caused by a defective gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. Most patients die in their mid-twenties.   (Reporting By Samantha Kareen Nair in Bengaluru; Editing by Savio D'Souza)",2015-07-02,VRTX,"Thu Jul 2, 2015 | 12:16pm EDT",Vertex Pharma's combination cystic fibrosis therapy wins FDA nod,http://www.reuters.com//article/vertexpharmaceutical-fda-idUSL3N0ZG5IS20150702?type=companyNews
26,"  Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Bioanalytical labs measures drug levels in biological samples, specifically in blood and urine. ""We are in the process of responding to the subpoena and intend to cooperate,"" Vertex said in a securities filing.The subpoena will not impact the safety, effectiveness and commercialization of the company's existing drugs or those in development, Vertex spokesman Zach Barber told Reuters. Shares of the cystic fibrosis drugmaker were marginally down after-hours.  Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had received subpoenas from federal agencies.CVS said the Drug Enforcement Administration (DEA) in September sought documents related to controlled substance policies, procedures and practices at eight pharmacy locations since May 2012. Last May the company agreed to a fine of $22 million in a settlement with the U.S. Attorneys Office for the Middle District of Florida, resolving alleged violations of the Controlled Substances Act.CVS, in its filing, said it is undergoing several audits by the DEA and is in discussions with the agency and the U.S. Attorney's office in several locations concerning allegations that it has violated certain requirements of the CSA.   Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters.""CVS and Mylan's shares were little changed after the bell. Neither company was immediately available for comment.  (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva and Leslie Adler)",2015-10-31,VRTX,"Fri Oct 30, 2015 | 9:07pm EDT",Vertex Pharma receives subpoena from Department of Justice,http://www.reuters.com//article/us-healthcare-subpeona-idUSKCN0SO2SS20151031?type=companyNews
27,"  (Adds Vertex response, details on CVS)Oct 30 Vertex Pharmaceuticals Inc said it received a subpoena from the U.S. Department of Justice in the third quarter related to its marketed medicines, seeking documents related primarily to its ""good laboratory practices"" in a bioanalytical lab.Good laboratory practices are rules that govern non-clinical safety studies, ensuring quality, integrity and reliability of data. Bioanalytical labs measures drug levels in biological samples, specifically in blood and urine.""We are in the process of responding to the subpoena and intend to cooperate,"" Vertex said in a securities filing.The subpoena will not impact the safety, effectiveness and commercialization of the company's existing drugs or those in development, Vertex spokesman Zach Barber told Reuters. Shares of the cystic fibrosis drugmaker were marginally down after-hours.Separately, drugmaker Mylan NV and drugstore chain CVS Health Corp said in their quarterly filings that they had received subpoenas from federal agencies. CVS said the Drug Enforcement Administration (DEA) in September sought documents related to controlled substance policies, procedures and practices at eight pharmacy locations since May 2012.Last May the company agreed to a fine of $22 million in a settlement with the U.S. Attorney's Office for the Middle District of Florida, resolving alleged violations of the Controlled Substances Act. CVS, in its filing, said it is undergoing several audits by the DEA and is in discussions with the agency and the U.S. Attorney's office in several locations concerning allegations that it has violated certain requirements of the CSA.Mylan said the U.S. Securities and Exchange Commission was seeking documents with regard to certain ""related party matters.""CVS and Mylan's shares were little changed after the bell. Neither company was immediately available for comment.    (Reporting by Natalie Grover and Ramkumar Iyer in Bengaluru; Editing by Anil D'Silva and Leslie Adler)",2015-10-31,VRTX,"Fri Oct 30, 2015 | 9:06pm EDT",UPDATE 1-Vertex Pharma receives subpoena from Department of Justice,http://www.reuters.com//article/healthcare-subpeona-idUSL3N12V00P20151031?type=companyNews
28,"  The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.The regulator rejected the company's application for using the drug in cystic fibrosis patients aged 2 or older, who have one of 23 residual function mutations. [The company's shares fell 7.7 pct to $9.60 in premarket trading. Cystic fibrosis is caused by a defective gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. Half of the people with cystic fibrosis live longer than 28 years, according to the World Health Organization.(bit.ly/1OqUj6Z) (Corrects fourth paragraph to ""Half of the people with cystic fibrosis live longer than 28 years, according to the World Health Organization"", from ""Most patients die in their mid-20s"")  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-02-05,VRTX,"Fri Feb 5, 2016 | 1:23pm EST",FDA rejects expanded use of Vertex's cystic fibrosis drug,http://www.reuters.com//article/us-vertex-pharms-fda-idUSKCN0VE1MQ?type=companyNews
29,"  The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.The regulator rejected the company's application for using the drug in cystic fibrosis patients aged 2 or older, who have one of 23 residual function mutations. [The company's shares fell 7.7 pct to $9.60 in premarket trading. Cystic fibrosis is caused by a defective gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. Half of the people with cystic fibrosis live longer than 28 years, according to the World Health Organization.(bit.ly/1OqUj6Z) (Corrects fourth paragraph to ""Half of the people with cystic fibrosis live longer than 28 years, according to the World Health Organization"", from ""Most patients die in their mid-20s"")  (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-02-05,VRTX,"Fri Feb 5, 2016 | 1:23pm EST",CORRECTED-FDA rejects expanded use of Vertex's cystic fibrosis drug,http://www.reuters.com//article/vertex-pharms-fda-idUSL3N15K4IB?type=companyNews
30,"  * Amounts to deferral of about $300 mln in U.S. revenue - analyst* Shares fall nearly 6 pct   (Adds analyst comment, share move)Feb 5 The U.S. Food and Drug Administration has denied the expanded use of Vertex Pharmaceutical Inc's  bestseller, Kalydeco, in certain cystic fibrosis patients, the company said on Friday.The regulator rejected the company's application for using the drug in cystic fibrosis patients aged 2 or older, who have one of 23 residual function mutations. [Vertex's shares fell nearly 6 percent to $86.34 in midday trading. Analysts, however, said the news reflected a minor setback for Vertex, considering the company is recruiting the same patient population into one of its late-stage trials.These trials should have results by mid-2017, which would suggest that the population could be included in the labeled indication 18-24 months from now if not immediately, Leerink Partners analysts said.""This amounts to a deferral of approximately $300 million in revenue potential in the U.S., and $225 million in Europe; however, we had assumed slower and lower penetration of this population in both geographies,"" they added. Cystic fibrosis is caused by defects in the CFTR gene that disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections.Half of the people with cystic fibrosis live longer than 28 years, according to the World Health Organization.(bit.ly/1OqUj6Z) Kalydeco, which brought in revenue of $632 million in 2015, is already approved to treat CF patients aged 2 and older with 10 different mutations in the CFTR gene.The company was exploring the use of the drug in the group of 23 residual function mutations, also known to carry the CFTR protein.Vertex said it had filed for an application based on studies of these mutations in preclincal trials and an exploratory mid-stage study.The FDA informed Vertex that it cannot approve the application in its present form. The company said it would meet with the regulator to determine the path forward.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)",2016-02-05,VRTX,"Fri Feb 5, 2016 | 12:49pm EST",UPDATE 2-FDA rejects expanded use of Vertex cystic fibrosis drug,http://www.reuters.com//article/vertex-pharms-fda-idUSL3N15K4IU?type=companyNews
31,"  LONDON, March 23 A new cystic fibrosis treatment from Vertex Pharmaceuticals has been rejected as too expensive by Britain's healthcare cost agency NICE.The National Institute for Health and Care Excellence (NICE) said on Wednesday that Orkambi, priced at an annual 104,000 pounds ($149,000) per patient, was not a cost-effective use of state healthcare resources, even though it offers clinical benefits. Vertex said it believed the evaluation process used by NICE in reaching its draft decision was not appropriate for rare diseases like cystic fibrosis, as it did not take into account the full benefits that medicines like Orkambi could offer. Cystic fibrosis is caused by a genetic defect that causes the lungs and digestive system to become clogged with sticky mucus. There is currently no cure. ($1 = 0.7000 pounds)   (Reporting by Ben Hirschler; Editing by Mark Heinrich)",2016-03-23,VRTX,"Tue Mar 22, 2016 | 8:01pm EDT","UK cost agency says ""no"" to pricey Vertex cystic fibrosis drug",http://www.reuters.com//article/vertex-pharms-britain-orkambi-idUSL5N16U3JI?type=companyNews
32,"  April 27 Vertex Pharmaceuticals Inc* Vertex reports first quarter 2016 financial results* Q1 earnings per share view $0.29 -- Thomson Reuters I/B/E/S * Q1 gaap loss per share $0.17 including items* Provides 2016 guidance for orkambi product revenues of $1.0 to $1.1 billion * Increases 2016 guidance for kalydeco product revenues to $685 to $705 million * Qtrly total cf product revenues $394 million versus $130 million* Q1 earnings per share view $0.29, revenue view $439.6 million -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-04-27,VRTX,"Wed Apr 27, 2016 | 4:28pm EDT",BRIEF-Vertex reports Q1 GAAP loss per share $0.17 including items,http://www.reuters.com//article/idUSASC08LUI?type=companyNews
33,  May 3 Vertex Pharmaceuticals Inc * Files for potential mixed shelf; size not disclosed - SEC filing  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)  ,2016-05-03,VRTX,"Tue May 3, 2016 | 5:48pm EDT",BRIEF-Vertex Pharmaceuticals files for potential mixed shelf,http://www.reuters.com//article/idUSFWN18015K?type=companyNews
34,"  May 25 Spero Therapeutics LLC* Has entered into an agreement with Vertex Pharmaceuticals* Deal to acquire worldwide rights to VXC-486/VXC-100 and a portfolio of innovative antibacterial compounds * Under terms of agreement, Spero will make an upfront payment to Vertex for portfolio rights * Under terms of agreement, Spero will assume responsibility for drug development and bringing compounds to market * Vertex will be eligible to get future devpt,commercial milestones, royalties on any therapeutic products resulting from agreement  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-25,VRTX,"Wed May 25, 2016 | 8:20am EDT",BRIEF-Spero Therapeutics to acquire worldwide rights to Vertex's VXC-486/VXC-100,http://www.reuters.com//article/idUSFWN18M0A3?type=companyNews
35,"  July 6 Vertex Pharmaceuticals Inc* Vertex and Moderna establish exclusive collaboration to discover and develop mrna therapeutics(tm) for cystic fibrosis* Vertex will also pay Moderna future development and regulatory milestones of up to $275 million * Vertex Pharmaceuticals says $275 million payment, including $220 million in reimbursement milestones, as well as tiered royalty payments on future sales* Vertex Pharmaceuticals Inc says Moderna to receive $40 million upfront, made up of a $20 million cash payment and a $20 million convertible note investment * Vertex and Moderna will conduct exclusive research, development and commercialization activities to advance mrna therapeutics * Will lead all preclinical, development and commercialization activities associated with advancement of mrna therapeutics* Will  fund all expenses related to collaboration  Source text for Eikon:  Further company coverage:    )",2016-07-06,VRTX,"Wed Jul 6, 2016 | 8:42am EDT",BRIEF-Vertex Pharmaceuticals and Moderna collaborate to discover and develop MRNA Therapeutics for cystic fibrosis,http://www.reuters.com//article/idUSFWN19S0F6?type=companyNews
36,"   By Carl O'Donnell and Ransdell Pierson  Medivation's MDVN.O $14 billion sale to U.S. drug giant Pfizer Inc (PFE.N) for a hefty premium, the largest U.S. biotechnology acquisition so far this year, had investors on Monday speculating about more dealmaking in the sector.Shares of Incyte Corp (INCY.O) and Seattle Genetics (SGEN.O), rose as much as 11 percent and 4 percent, respectively. Incyte and Seattle Genetics, which have respective market capitalizations of $15.4 billion and $6.7 billion, focus on innovative cancer treatments and, like Medivation, are already producing revenue.For the other companies that also bid for Medivation, including Sanofi SA (SASY.PA), Merck & Co Inc (MRK.N), Celgene Corp (CELG.O) and Gilead Sciences Inc (GILD.O), such targets could serve as coveted consolation prizes.  Major drug makers are vying for a foothold in oncology because the sector promises to be among the single biggest contributors to sales growth over the next five years, according to data from consultancy Ernst and Young. Large pharmaceutical companies have been itching to make big deals all year. The most deal-hungry are wrestling with generic competition, or are rushing to gain a leadership position in a burgeoning therapeutic area, such as cancer or rare diseases. This acquisition drive could spell deals even for other promising biotechnology companies outside the oncology sector. Shares of BioMarin Pharmaceutical Inc (BMRN.O) for example, a $16.7 billion market capitalization company that focuses on rare diseases, rose as much as 7 percent on takeover speculation.Pfizer's acquisition of Medivation for $81.50 per share in cash, represents a close to 120-percent premium to Medivation's stock price before Reuters reported on March 30 that the company was working with JPMorgan Chase & Co (JPM.N) to field takeover approaches.It is a rich valuation by most metrics. The deal values Medivation at 17.9 times its revenue, versus a 12.8 times average for deals in the sector in the last eight years, according to a research note by BMO Capital Markets.  The deal could be a much needed shot in the arm for dealmaking in the biotech sector, which has been tepid ever since the Nasdaq Biotech Index .NBI plunged more than 30 percent late last year, largely due to heightened political pressure on drug prices.So far this year, dealmaking activity in life sciences is down 64 percent from this time last year, according to data from Thomson Reuters.  But that could change as the corporate boards of mid-sized biotech companies, which have been hesitant to seriously consider a sale in a down market, are tempted by the prospect of juicy premiums, investors, analysts and investment bankers said.""Given the scarcity of mid-cap biotech, we believe the remaining companies could see increasing interest, as large pharma continues to look toward biotech as a source of growth,"" Do Kim, an analyst for BMO Capital Markets, wrote in his note.Other companies to watch for as possible acquisition targets include Vertex Pharmaceuticals Inc (VRTX.O), Alexion Pharmaceuticals Inc (ALXN.O), Neurocrine Biosciences Inc (NBIX.O) and Intercept Pharmaceuticals Inc (ICPT.O), Kim noted. (Reporting by Carl O'Donnell and Ransdell Pierson in New York; Editing by Greg Roumeliotis and Nick Zieminski)",2016-08-22,VRTX,"Mon Aug 22, 2016 | 4:30pm EDT",Pfizer's Medivation buy seen prescribing more biotech M&A,http://www.reuters.com//article/biotechnology-ma-idUSL1N1B30ZB?type=companyNews
37,"  Sept 28 Vertex Pharamceuticals Inc said the U.S. Food and Drug Administration expanded the use of its cystic fibrosis drug to treat a new subgroup of patients with the rare genetic disorder.The company, however, cut its 2016 sales forecast for the drug, Orkambi, sending its shares down as much as 4 percent in after-market trading on Wednesday.Vertex cited a slower-than-anticipated launch in Germany and slower refills during July and August for the cut.The company said it now expects Orkambi revenue of $950 million to $990 million, down from $1.0 billion to $1.1 billion it had previously forecast. The FDA approved the use of Orkambi in children with cystic fibrosis aged 6-11 who have a type of the mutation. The drug is already approved for use in patients aged 12 and older with a similar mutation. ""(The) approval in people ages 6 through 11 will drive growth in the U.S. in the fourth quarter,"" the company said.Cystic fibrosis is a life-threatening condition, where a defective gene disrupts the function of the lungs and digestive system, producing a build-up of thick, sticky mucus leading to inflammation and recurrent bacterial infections. The company's shares recouped some of their losses to be down less than a percent in extended trading. Up to Wednesday's close of $88.84, the stock had fallen about 29 percent this year.(Reporting by Dipika Jain in Bengaluru; Editing by Sriraj Kalluvila)",2016-09-28,VRTX,"Wed Sep 28, 2016 | 6:16pm EDT",FDA approves expanded use of Vertex Pharma's cystic fibrosis drug,http://www.reuters.com//article/vertex-pharms-fda-idUSL3N1C44M0?type=companyNews
38,"  Oct 14 Vertex Pharmaceuticals Inc* Vertex Pharma - on oct 13 amended and expanded research, development and commercialization agreement with cystic fibrosis foundation therapeutics inc * Vertex Pharma - amendment provides for upfront program award from cfft to us of $75.0 million,development funding from cfft to us of upto $6.0 million annually * Vertex Pharmaceuticals Inc-  pursuant to amendment , co will continue to pay royalties ranging from low single digits to mid-single digits * Vertex Pharma-entered into data license deal with Cystic Fibrosis Foundation, co will pay for continuing access to data from CFF's patient registry  Source text - bit.ly/2eom87x Further company coverage:",2016-10-14,VRTX,"Fri Oct 14, 2016 | 8:28am EDT",BRIEF-Vertex Pharma: Amended and expanded agreement with Cystic Fibrosis Foundation Therapeutics,http://www.reuters.com//article/idUSFWN1CK0CQ?type=companyNews
39,"  Oct 25 Vertex Pharmaceuticals Inc* Vertex reports third quarter 2016 financial results* Q3 non-GAAP earnings per share $0.16 * Q3 GAAP loss per share $0.17* Q3 earnings per share view $0.18 -- Thomson Reuters I/B/E/S * Vertex Pharmaceuticals Inc - reiterated financial guidance for total 2016 ORKAMBI and KALYDECO revenues and expenses * Vertex Pharmaceuticals Inc says Q3 net product revenues from ORKAMBI were $234.0 million compared to $130.8 million for Q3 of 2015* Vertex Pharmaceuticals Inc says Q3 net product revenues from KALYDECO were $175.6 million, compared to $165.9 million for Q3 of 2015  Source text for Eikon:  Further company coverage:",2016-10-25,VRTX,"Tue Oct 25, 2016 | 4:25pm EDT",BRIEF-Vertex Pharmaceuticals Q3 adj. earnings 16 cents/share,http://www.reuters.com//article/idUSASC09CYY?type=companyNews
40,  Oct 25 Vertex Pharmaceuticals Inc* Announces planned initiation of phase 2 studies evaluating the next-generation correctors VX-440 and VX-152 in triple combination regimens to treat the underlying cause of cystic fibrosis * Says data from study of VX-152 are expected in second half of 2017  * Says has submitted ind applications to FDA for both VX-440 and VX-152 and expects to start both studies by end of 2016  Source text for Eikon:  Further company coverage:,2016-10-25,VRTX,"Tue Oct 25, 2016 | 4:17pm EDT",BRIEF-Vertex says data from study of VX-152 expected in second half of 2017,http://www.reuters.com//article/idUSFWN1CV119?type=companyNews
